REFERENCES:

1. Yu LX. Pharmaceutical quality by design: Product and process development, understanding, and control. Pharm Res 2008;25(4):781-791.
2. Riley BS, Li X. Quality by Design and Process Analytical Technology for Sterile Products-Where Are We Now? AAPS PharmSciTech 2010:1-5.
3. Korakianiti E, Rekkas D. Statistical Thinking and Knowledge Management for Quality-Driven Design and Manufacturing in Pharmaceuticals. Pharm Res 2010:1-15.
4. Snee RD. Quality by design: Experimental strategies for implementing quality by design. Pharmaceutical Processing 2010;25(4):12-16.
5. ICH Q8, Pharmaceutical Development, Step 4 version, 2005.
6. Cogdill RP, Drennen JK. Risk-based quality by design (QbD): A Taguchi perspective on the assessment of product quality, and the quantitative linkage of drug product parameters and clinical performance. Journal of Pharmaceutical Innovation 2008;3(1):23-29.
7. Huang J, Kaul G, Cai C, Chatlapalli R, Hernandez-Abad P, Ghosh K, et al. Quality by design case study: An integrated multivariate approach to drug product and process development. Int J Pharm 2009;382(1-2):23-32.
8. Nasr M, Migliaccio G, Allen B, Baum R, Branning R, Chen C-, et al. FDA's pharmaceutical quality initiatives: Implementation of a modern risk-based approach. Pharm Technol 2008;32(5):54-72.
9. Gray V, Kelly G, Xia M, Butler C, Thomas S, Mayock S. The Science of USP 1 and 2 Dissolution: Present Challenges and Future Relevance. Pharm Res 2009:1-14.
10. Drennen III JK. Quality by design - What does it really mean? Journal of Pharmaceutical Innovation 2007;2(3-4):65-66.
11. Al-Hallak MHDK, Azarmi S, Xu Z, Maham Y, Löbenberg R. Isothermal microcalorimetry as a quality by design tool to determine optimal blending sequences. AAPS Journal 2010;12(3):417-423.
12. Mire-Sluis A, Schenerman M, Mhatre R, Advant S, Dougherty J, Kozlowski S, et al. Quality by design: The next phase. BioProcess International 2009;7(1):34-42.
13. Short SM, Cogdill RP, D'Amico F, Drennen JK, Anderson CA. A new definition of pharmaceutical quality: Assembly of a risk simulation platform to investigate the impact of manufacturing/product variability on clinical performance. J Pharm Sci 2010;99(12):5046-5059.

14. Henck J-, Byrn SR. Designing a molecular delivery system within a preclinical timeframe. Drug Discov Today 2007;12(5-6):189-199.
15. Rathore A. Quality by Design for biotechnology products: Challenges and solutions. Pharmaceutical Technology Europe 2010;22(2):21-22.
16. Somma R. Development knowledge can increase manufacturing capability and facilitate quality by design. Journal of Pharmaceutical Innovation 2007;2(3-4):87-92.
17. Lionberger RA. FDA critical path initiatives: Opportunities for generic drug development. AAPS Journal 2008;10(1):103-109.
18. Neway J. How to make the business case for quality by design. BioPharm International 2008;21(12):42-47.
19. Costioli MD, Guillemot-Potelle C, Mitchell-Logean C, Broly H. Cost of goods modeling and quality by design for developing cost-effective processes. BioPharm International 2010;23(6):26-35.
20. Nowrangi MA, Rao V, Lyketsos CG. Epidemiology, assessment, and treatment of dementia. Psychiatr Clin North Am. 2011;34:275–294.
21. 2. Thies W, Bleiler L, for the Alzheimer's Association. 2011 Alzheimer's disease facts and figures. Alzheimers Dement. 2011;7:208–244.
22. Hashizume. Preventive/Therapeutic Agent for Alzheimer’s Dementia. European patent WO 2007/064010.
23. Blake Paterson etal. Antitissue compositions of comparising Memaintine, US patent WO 2014/0200271 A1.
24. Vrbinc, Miha. Pharmaceutical composition containing stabilised amorphous form of Donepezil hydrochloride, European patent, WO 2004/000317.
25. Shah Rajen. Oral controlled release formulations, European patent,WO 2001/022944.
26. Mcdonald, Scott. Memantine for the treatment of mild-to-moderate Alzheimer’s disease. European patent, WO 2005/067908.
27. Jahuhari Pradeep Kumar. Process for preparing Memantine hydrochloride substantially free of impurities, International Application Published under the Patent Cooperation Treaty, WO 2009/153806 A2.
28. Johanston Lynsey. Novel assay for the analysis of Memantine and related compounds, International Application Published under the Patent Cooperation Treaty, WO 2009/010806 Al.
29. Firestone Bruce A. Memantine oral dosage forms, International Application Published under the Patent Cooperation Treaty, WO 2004/112768 Al.

30. Kushner J, Langdon BA, Hicks I, Song D, Li F, Kathiria L. A quality-by-design study for an immediate-release tablet platform: examining the relative impact of active pharmaceutical ingredient properties, processing methods, and excipient variability on drug product quality attributes. J Pharm Sci. 2014 Feb; 103(2):527-38.
31. Kushner J 4th1, Langdon BA, Hiller JI, Carlson GT. Examining the impact of excipient material property variation on drug product quality attributes: a quality-by-design study for a roller compacted, immediate release tablet. J Pharm Sci. 2011 Jun;100(6):2222-39
32. Amende MT1, Moses SK, Carella AJ, Gadkari RA, Graul TW, Otano AL, Timpano RJ Improving the content uniformity of a low-dose tablet formulation through roller compaction optimization. Pharm Dev Technol. 2007;12(4):391-404
33. Hancock BC1, Garcia-Munoz S. How do formulation and process parameters impact blend and unit dose uniformity? Further analysis of the product quality research institute blend uniformity working group industry survey. J Pharm Sci. 2013 Mar;102(3):982-6
34. Patel S1, Kaushal AM, Bansal AK. Compression physics in the formulation development of tablets. Crit Rev Ther Drug Carrier Syst. 2006;23(1):1-65
35. Tye CK1, Sun CC, Amidon GE. Evaluation of the effects of tableting speed on the relationships between compaction pressure, tablet tensile strength, and tablet solid fraction. J Pharm Sci. 2005 Mar;94(3):465-72
36. Sun C1, Grant DJ. Influence of crystal shape on the tableting performance of L-lysine monohydrochloride dehydrate. J Pharm Sci. 2001 May;90(5):569-79
37. Juan Manuel Maler, Hermann Esselmann, Jens Wiltfang, Nikolaus Kunz, Piotr Lewczuk. Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons. Brain Research 1052 (2005) : 156– 162
38. Zhiming Xia, Rui Zhang, Pingping Wu, Zongqin Xia, Yaer Hu. Memory defect induced by beta-amyloid plus glutamate receptor agonist is alleviated by catalpol and donepezil through different mechanisms. Brain Research 1441 (2012) : 27-37
39. Shadabul Haque, Shadab Md, Jasjeet Kaur Sahni, Javed Ali, Sanjula Baboota. Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression. Journal of Psychiatric Research 48 (2014) : 1-12
40. Ernesto Tarragon, Dolores Lopez, Cristina Estrada, Ana Gonzalez-Cuello, Carmen Ma Ros, Yves Lamberty Memantine prevents reference and working memory impairment caused by sleep deprivation in both young and aged Octodon degus. Neuropharmacology 85 (2014):206-214.

41. Teresa A Barber, Ryan A. Meyers 1, Brian F McGettigan. Memantine improves memory for taste-avoidance learning in day-old chicks exposed to isolation stress Pharmacology, Biochemistry and Behavior 95 (2010):203–208.
42. Alexis Kays Leonard, Anthony P Sileno, Gordon C Brandt, Charles A. Foerder, Steven C Quay, Henry R Costantino. In vitro formulation optimization of intranasal Galantamine leading to enhanced bioavailability and reduced emetic response in vivo. International Journal of Pharmaceutics 335 (2007):138–146.
43. Ziyaur Rahman, Akhtar Siddiqui, Mansoor A. Khan. Orally disintegrating tablet of novel salt of antiepileptic drug: Formulation strategy and evaluation. European Journal of Pharmaceutics and Biopharmaceutics 85 (2013):1300–1309.
44. Ronald Black, Barry Greenberg, J Michael Ryan, Holly Posner, Jeffrey Seeburger, Joan Amatniek, Malca Resnick, Richard Mohs. Scales as outcome measures for Alzheimer's disease. Alzheimer's & Dementia 5 (2009): 324–339.